CD22 functions primarily as a negative regulator of B-cell receptor signaling. The Cd22 a allele has been proposed as a candidate allele for murine systemic lupus erythematosus. In this study, we explored the possible expression of aberrant forms of CD22, which differ in the N-terminal sequences constituting the ligand-binding site due to synthesis of abnormally processed Cd22 mRNA, in several Cd22 a mouse strains, including C57BL/6 Cd22 congenic mice. The staining pattern of splenic B cells obtained with CY34 anti-CD22 mAb, which was expected to bind poorly to the aberrant CD22, was more heterogeneous in Cd22 a mice than in Cd22 b mice. Moreover, CD22 detected on B cells of Cd22 a mice was expressed more weakly and as a smaller-sized protein, compared with Cd22 b mice. Significantly, analysis with a synthetic CD22 ligand demonstrated that Cd22 a mice carried a larger proportion of CD22 that was not bound by cis ligands on the B-cell surface than Cd22 b mice. Finally, the study of C57BL/6 Cd22 congenic mice revealed that Cd22 a B cells displayed a phenotype reminiscent of constitutively activated B cells (reduced surface IgM expression and augmented MHC class II expression), as reported for B cells expressing a mutant CD22 lacking the ligand-binding domain. Our demonstration that Cd22 a B cells express aberrant forms of CD22, which can potentially deregulate B-cell signaling because of their decreased ligand-binding capacity, provides further support for Cd22 a as a potential candidate allele for murine systemic lupus erythematosus.
Introduction
CD22 is a B cell-specific member of the Ig superfamily with seven Ig-like domains, which functions as an adhesion receptor recognizing a2,6-linked sialic acid (2,6Sia)-bearing glycans on target cells, and as a co-receptor for B-cell receptor (BCR) (1) . Upon BCR cross-linking, CD22 is rapidly tyrosine phosphorylated on its cytoplasmic tail, which results in recruitment and activation of SH-2 phosphotyrosine phosphatase (SHP-1), thereby negatively regulating BCR signaling (2) . Furthermore, the finding that CD22-deficient B cells exhibit a greatly enhanced and prolonged Ca 2+ signal after BCR stimulation (3) (4) (5) (6) indicates that CD22 functions primarily as a negative regulator of BCR signaling by controlling the threshold of BCR-mediated signal transduction. CD22deficient B cells also show higher tyrosine phosphorylation of several signaling molecules which positively regulate Ca 2+ mobilization (1) . One mechanism by which CD22 regulates Ca 2+ signaling has recently been uncovered: CD22 attenuates calcium efflux by activating a plasma membrane calcium-ATPase, the activation of which requires tyrosine phosphorylation of CD22 and SHP-1 (7) .
CD22 is a member of the sialic acid-binding Ig-like lectin (Siglec) family of adhesion receptors, which bind specifically to sialic acids in characteristic linkages (8) . CD22 has a specificity for 2,6Sia, a common structure on N-linked glycans that are abundantly expressed on the surface of many cells (9, 10) . CD22 binds to 2,6Sia with its first Ig-like domain (11, 12) . The affinity of CD22 for sialic acids is very low and does not differ greatly for several sialylated proteins, suggesting that it is just the presence and density of the carbohydrate, but not the protein backbone, that determines ligand binding (13) . It has been shown that CD22 is constitutively bound to ligands in cis, i.e. to ligands on the same cellular surface, on the majority of both human and mouse B cells (14) (15) (16) . These cis interactions seem to regulate the inhibitory signaling function of CD22, because when they were blocked in established B-cell lines, lower tyrosine phosphorylation of CD22 and higher Ca 2+ signaling after BCR activation were observed (17, 18) . Recently, a CD22 knock-in mouse with a mutated CD22 ligand-binding domain confirmed the important biological role of 2,6Sia binding for CD22 (19) . However, enhanced Ca 2+ signaling was not observed in this knockin mouse.
The CD22 a protein carries a 6-amino-acid deletion and 8-amino-acid substitutions in the first Ig-like domain, as compared with CD22 b (20) . In addition, we have demonstrated that the Cd22 a gene contains a short interspersed nucleotide element insertion in the second intron (21) . As a consequence, Cd22 a B cells synthesize abnormally processed Cd22 mRNA, which contains insertions of~20-120 nucleotides between exons 2 and 3, and/or deletions of~100-190 nucleotides in exon 4 encoding the first Ig-like domain of CD22. Thus, it has been speculated that Cd22 a B cells could express aberrant forms of CD22, which differ in the N-terminal sequences constituting the ligand-binding site (17, 18, 22) . We explored this possibility by assessing the binding to B cells of two different anti-CD22 mAb, CY34 and NIM-R6, which apparently recognize an epitope present in the first or fourth Ig-like domain, respectively (22, 23) , and by analyzing the expression of aberrant CD22 protein from Cd22 a mice by Western blot. In addition, we determined the binding capacity of B cells from different mouse strains bearing either the Cd22 a or Cd22 b allele for a synthetic ligand containing 2,6Sia. Our results demonstrate that a larger proportion of CD22 is not bound by cis ligand on Cd22 a B cells, as compared with Cd22 b B cells, indicating the expression of aberrant forms of CD22 with a decreased ligand-binding capacity in Cd22 a mice.
Methods
Mice C57BL/6 (B6; Cd22 b ), BALB/c (Cd22 b ), C3H (Cd22 b ), DBA/2 (Cd22 a ), NZB (Cd22 a ) and NZW (Cd22 a ) mice were purchased from the Jackson Laboratories, Bar Harbor, ME, USA. CD22 ÿ/ÿ mice with a pure B6 background were developed as described previously (6) . B6 mice bearing the Cd22 a allele were generated by backcross procedures using markerassisted selection, as described previously (24) .
Flow cytometric analysis
Flow cytometry was performed using two-color staining of lymphocytes, and analyzed with a FACSCalibur (BD Biosciences, San Jose, CA, USA). The following antibodies and reagents were used: FITC-labeled NIM-R6 rat anti-CD22 (20), FITC-labeled CY34 rat anti-CD22 (25), FITC-labeled rat IgG, polyclonal rabbit anti-CD22 antibodies, raised against Ig-like domains 1-3 of the CD22 b protein by immunizing rabbits with a CD22 domains 1-3-Fc fusion protein, and affinity purified (the expression construct was generously provided by A. van der Merwe, Oxford and P. Crocker, Dundee), FITC-labeled goat anti-rabbit IgG, FITC-or PE-labeled RA3-6B2 rat anti-B220, PE-labeled 53-7.3 rat anti-CD5, biotinylated 7G6 rat anti-CD21, FITC-labeled LO-MM9 rat anti-mouse IgM and FITC-labeled Y-3P anti-I-A b .
Western blot analysis
Total lysates of spleen cells from 2-month-old B6, BALB/c, DBA/2 and NZB mice were separated by a 6% SDS-PAGE and transferred to Immobilon-P transfer membrane (Millipore, Volketswil, Switzerland) with a semi-dry blotting apparatus (BioRad, Glattbrugg, Switzerland). After 2 h of blocking at room temperature in TTBS (10 mM Tris-HCl, pH 7.4, 100 mM NaCl and 0.05% Tween 20) containing 5% low-fat, dry milk powder (TTBS-MP), the membranes were incubated with polyclonal rabbit anti-CD22 antibodies in TTBS-MP overnight at 4°C. Polyclonal rabbit anti-LYN antibodies (Santa Cruz Biotechnology, Heidelberg, Germany) were used as a loading control. Thoroughly washed membranes were incubated with HRP-conjugated goat anti-rabbit IgG (BioRad) for 1 h at room temperature. Chemiluminescence development was carried out with the enhanced chemiluminescence reagents (Amersham Bioscience, Dü bendorf, Switzerland) and the membranes were exposed to HyperFilm ECL (Amersham).
Cell culture
A total of 2 3 10 6 spleen cells from a pool of 2-month-old mice were incubated in 1 ml of DMEM containing 10% FCS in Falcon 24-well plates in the presence of 25 lg ml ÿ1 LPS for 48 h. Then, the expression of CD22 on B cells was determined by flow cytometric analysis. B cells were purified from spleen by adherence of macrophages to plastic plates for 1 h at 37°C and subsequent treatment with anti-Thy-1.2 (AT-83) mAb in the presence of rabbit complement. The purity of B cells, as documented by cytofluorometric analysis, was superior to 95%. B-cell proliferative responses were determined by incubating 2 3 10 5 spleen cells from B6 mice with different concentrations of rat b7-6 anti-mouse IgM mAb, rat FGK45 anti-mouse CD40 mAb or LPS in a total volume of 200 ll DMEM containing 10% FCS. Cultures were pulsed with 1 lCi of [ 3 H]thymidine for the final 6 h of 3-day culture, harvested and counted for radioactivity.
Staining of cells with a synthetic CD22 ligand
Preparation and use of the synthetic probe, N-glycolylneuramic acid-galactose-N-acetylglucosamine-streptavidin-alkaline phosphatase (NeuGca2,6Gal-SAAP), have been described in detail elsewhere (16) . NeuGca2,6Gal-SAAP consists of the sialoside NeuGca2,6Gala1,4GlcNAc-biotin, bound to streptavidin-alkaline phosphatase, which is then FITC-labeled. The probe used for the experiments here is a new preparation which gives a higher degree of background staining with CD22 ÿ/ÿ B cells, than previously (16) . For staining, singlecell suspensions were prepared from total spleen. Prior to FACS analysis, all cells were depleted of erythrocytes by lysis with hypotonic Gey's solution. Sialidase treatment was performed with 0.1 U ml ÿ1 neuraminidase of Arthrobacter ureafaciens (Roche Applied Science, Mannheim, Germany) for 1 h at 37°C in PBS-0.1% BSA. A total of 1 3 10 5 to 2 3 10 5 erythrocyte-depleted splenic cells were first stained with anti-B220 mAb. Staining with FITC-labeled NeuGca2,6Gal-SAAP was performed by incubating the cells with the probe for 45 min on ice. Flow cytometry was performed as described above.
Ca 2+ mobilization measurements
Spleen cells were loaded with Indo-1 (Molecular Probes, Eugene, OR, USA), as described (17, 18) , and stained with FITC-labeled anti-B220 mAb. Splenocytes were then stimulated with 10, 30 or 90 lg ml ÿ1 of b7-6 anti-IgM mAb at 37°C, and increases in intracellular free Ca 2+ in B220 + B cells were measured in real time with the use of a FACSVantage (BD Biosciences). The recorded files were transferred to FlowJo software (Tree Star, Ashland, OR, USA), and the median of each sample was calculated.
Results

Heterogeneous staining pattern of Cd22 a B cells with CY34, but homogeneous staining pattern with NIM-R6
When splenic B cells from 2-month-old DBA/2 (Cd22 a ), NZB (Cd22 a ), NZW (Cd22 a ), B6 (Cd22 b ) and BALB/c (Cd22 b ) mice were stained with FITC-labeled CY34 mAb, the intensity of surface staining on Cd22 a B220 + B cells, gated using PElabeled anti-B220 mAb, was lower than that of Cd22 b B cells ( Fig. 1 ). Moreover, it was striking to see that the staining pattern of B cells with the CY34 mAb was more heterogeneous in the three strains of mice bearing the Cd22 a allele than that of Cd22 b B6 and BALB/c mice ( Fig. 1 ). In contrast, splenic B cells from the three different Cd22 a strains exhibited a homogeneous staining pattern by FITC-labeled NIM-R6 mAb, similar to that observed in Cd22 b mice. Notably, the intensity of NIM-R6 staining on Cd22 b B cells was significantly higher than that observed on Cd22 a B cells, although the differences were relatively small (P < 0.005). These results suggested that, unlike CD22 expressed by mice carrying the Cd22 b allele, CD22 molecules on B cells from mice bearing the Cd22 a allele were more heterogeneous because of differences in their N-terminal region. This is consistent with the finding that Cd22 a B cells express multiple forms of Cd22 mRNA transcripts having highly variable N-terminal sequences coding for the first Ig-like domain.
Expression of smaller-sized CD22 proteins in Cd22 a B cells than in Cd22 b B cells
To further address whether aberrant forms of CD22 protein are expressed in B cells of Cd22 a mice, splenic B cells were analyzed with a polyclonal rabbit anti-CD22 antibody raised against murine CD22 b (Ig-like domains 1-3). Western blot analysis revealed that CD22 migrated as a slightly smallersized protein in B cells from Cd22 a mice (DBA/2 and NZB) than CD22 detected in B cells from Cd22 b mice (B6 and BALB/c) ( Fig. 2A ). We also noted lower intensities of the CD22 bands in Cd22 a mice. This was confirmed by flow cytometric analysis, showing that the intensity of rabbit anti-CD22 staining on the surface of Cd22 a B cells was significantly lower than that on the surface of Cd22 b B cells (Fig. 2B ). These differences could be explained by two reasons: a lower expression of CD22 protein by Cd22 a mice and a lower reactivity to CD22 a of the rabbit anti-CD22 antibodies used in this analysis because these antibodies were raised against a polypeptide spanning the first three Ig-like domains in which substantial amino-acid substitutions were identified between the CD22 a and CD22 b proteins (22, 23) . We have previously observed, by staining with NIM-R6 mAb, that B cells of NZW (Cd22 a ) mice up-regulated CD22 less efficiently after activation with LPS in the presence of IL-4 than those of B6 (Cd22 b ) mice (21) . To further define the expression of aberrant and intact CD22 in Cd22 a B cells, we compared the level of CD22 molecules detectable by CY34 or NIM-R6 mAb after incubation of spleen cells with LPS. After 48 h of LPS stimulation, splenic B cells from Cd22 a (DBA/2, NZB and NZW) mice displayed increases in CD22 levels detectable by NIM-R6 mAb, though less than those observed in Cd22 b (B6 and BALB/c) mice (Fig. 3 ). In contrast, the level of CD22 recognized by CY34 mAb was barely increased in Cd22 a B cells, as compared with Cd22 b B cells, probably due to the presence of CD22 molecules with an aberrant first Ig-like domain that were poorly detected by CY34 mAb. Significantly, after LPS stimulation of splenic B cells from NZW and NZB mice, we observed a substantial increase in the number of B cells expressing aberrant CD22, which was very poorly recognized by the CY34 mAb. It should be mentioned that the CY34 lo subset did not express CD5 at a significant level (data not shown), indicating that these were not B-1 cells present in high numbers in NZB mice (26) . Since an expansion of the CY34 lo subset was not observed in LPS-stimulated spleen cells from non-autoimmune DBA/2 mice, this finding is likely related to the particular genetic background of autoimmuneprone NZW and NZB mice. All these data support the expression of aberrant forms of CD22 on the surface of Cd22 a B cells.
Increased binding by Cd22 a B cells to a synthetic CD22 ligand
Since the CD22 a protein carries mutations in exon 4 coding for the ligand-binding first Ig-like domain (20) , we tested whether sialic acid binding is affected by these mutations. To examine the ligand-binding capacity of CD22 a in situ on the surface of B cells, we used a synthetic probe, NeuGca2,6Gal-SAAP which carries 2,6Sia coupled as an oligomer to streptavidin. As previously described (16) , most CD22 on the surface of B cells of B6 mice (Cd22 b ) was 'masked' by binding to endogenous ligands in cis and therefore could not be stained by the probe NeuGca2,6Gal-SAAP (Fig. 4A ). However, there was a sub-population (~10%) of B cells with 'unmasked' CD22, which could be stained with NeuGca2,6Gal-SAAP. Next, we compared the NeuGca2,6Gal-SAAP binding with B cells from three strains of Cd22 b mice with three strains of Cd22 a mice. The Cd22 b strains B6, BALB/c and C3H showed on average 10-11% of B cells which were stained with the probe (Fig. 4A) . In contrast, for the Cd22 a strains NZB, NZW and DBA/2 probe binding to B cells was significantly increased (1.5-to 1.8-fold). This indicated a higher degree of unmasked, i.e. not cisbound, CD22 in the Cd22 a strains. Not all probe binding was CD22 specific, as can be seen by staining of B cells from CD22-deficient mice. Residual binding of NeuGca2,6Gal-SAAP to CD22 ÿ/ÿ B cells could be due to other Siglecs expressed, or could be unspecific binding.
Then, we tested the capacity of CD22 a and CD22 b to bind the synthetic probe after removal of cis ligands from the surface of B cells by sialidase treatment. After a treatment with sialidase, B cells from all CD22-sufficient mice showed increased binding of the NeuGca2,6Gal-SAAP probe (Fig. 4B) . However, under the sialidase treatment conditions used, there was still a difference between B cells from Cd22 b and Cd22 a mice, and B cells from Cd22 a mice showed a clearer shift toward probe-stained cells. As expected, the majority of CD22 ÿ/ÿ B cells still failed to bind the probe after this treatment (Fig. 4B) . These results indicate that not all 2,6Siacontaining CD22 ligands on CD22 b -expressing cells can be removed by sialidase treatment as easily as on CD22 aexpressing cells, suggesting that the former are less accessible. It should, however, be mentioned that Cd22 a B cells from NZB, NZW and DBA/2 mice did not show any significant differences in Ca 2+ influx following BCR cross-linking with b7-6 anti-IgM mAb at any dose tested, as compared with Cd22 b B cells from B6, BALB/c and C3H mice (data not shown).
Defective expression of CD22 in B cells from B6 Cd22 a congenic mice
In order to exclude that the observed differences between Cd22 a and Cd22 b mice are due to unspecific strain background effects, B6 Cd22 a congenic mice were produced by backcross procedures and analyzed for the staining of splenic B cells with different anti-CD22 antibodies in comparison with that of Cd22 b B cells from conventional B6 mice. As observed in different strains of Cd22 a and Cd22 b mice, B6 Cd22 a B cells displayed weak and heterogeneous staining with CY34 mAb, and less strong staining with NIM-R6 mAb and polyclonal rabbit anti-CD22 antibodies, as compared with conventional B6 Cd22 b B cells (Fig. 5A) . Moreover, Western blot analysis confirmed the expression of a smallersized CD22 protein in B6 Cd22 a B cells than in Cd22 b B cells (Fig. 5B) . Furthermore, the binding study with synthetic NeuGca2,6Gal-SAAP probe on untreated and sialidasetreated B cells demonstrated the presence of a larger proportion of unmasked CD22 on B6 Cd22 a B cells than on B6 Cd22 b B cells (P < 0.05; Fig. 6 ). Notably, the analysis of B-cell subsets in spleen by staining with anti-IgM and anti-CD21 mAb revealed that percentages of transitional 1 (T1; CD21 ÿ IgM hi ), T2 and marginal zone (CD21 hi IgM hi ), and follicular (CD21 int IgM int ) B cells in B6 Cd22 a mice (means 6 SD of three mice: T1, 6.6 6 0.4%; T2 + marginal zone, 5.3 6 0.7%; follicular, 45.1 6 1.9%) were essentially identical to those from B6 Cd22 b mice (T1: 7.2 6 1.1%; T2 + marginal zone: 6.4 6 0.9%; follicular: 43.2 6 0.2%). These data argued against the possibility that an imbalance in splenic B-cell subsets accounted for the higher unmasking of CD22 in Cd22 a mice.
Activated phenotype of B cells from B6 Cd22 a congenic mice
Studies with B cells expressing a mutant CD22 lacking the ligand-binding domain displayed a phenotype of constitutively activated B cells, as documented by reduced expression of IgM and increased expression of MHC class II on the surface of mature B cells (19) . Therefore, we determined expression levels of surface IgM and MHC class II I-A molecules on splenic B cells from B6 Cd22 a mice in comparison with those on Cd22 b B cells. Cd22 a B cells were found to express significantly less surface IgM (mean fluorescence intensity: 59.9 6 2.0) and more MHC class II I-A (172.0 6 5.7) than B cells from Cd22 b counterparts (IgM, 65.6 6 0.6; I-A, 151.1 6 8.1; Fig. 7A ).
It has also been reported that anti-IgM-and anti-CD40induced B-cell proliferative responses were substantially reduced and modestly augmented, respectively, in mice expressing the mutant CD22 (19) . Although we did not observe measurable differences in B-cell proliferative responses after stimulation with anti-CD40 mAb or LPS, BCRinduced proliferation after treatment with anti-IgM mAb was substantially reduced in Cd22 a B cells, compared with that of Cd22 b B cells (Fig. 7B) . Despite significant reduced proliferative responses, Cd22 a B cells had Ca 2+ mobilization comparable to that of Cd22 b B cells after stimulation with anti-IgM mAb (Fig. 7C) , consistent with the results obtained with B cells expressing the mutant CD22 (19) . 
Discussion
We explored the possible expression of aberrant forms of CD22 on B cells from several Cd22 a mouse strains, including Cd22 a congenic C57BL/6 mice, by surface staining with CY34 and NIM-R6 anti-CD22 mAb, which recognize distinct epitopes of CD22, by Western blot, and by use of a synthetic CD22 ligand. Our data support the notion that Cd22 a B cells express aberrant forms of CD22 molecule that differ in the N-terminal region constituting the ligand-binding site for 2,6Sia-bearing glycans, as compared with CD22 b molecules. The analysis with a synthetic CD22 ligand revealed that CD22 protein from Cd22 a mice is less bound to endogenous ligands on the B-cell surface than their counterpart from Cd22 b strains, indicating a decreased ligand-binding capacity of CD22 a protein. This was further supported by the analysis of B6 Cd22 congenic mice, which revealed that Cd22 a B cells displayed a phenotype reminiscent of constitutively activated B cells, as characterized by reduced surface IgM expression and augmented MHC class II expression, similar to that reported for B cells expressing a mutant CD22 lacking the ligand-binding domain (19) .
The full-length CD22 a protein carries a 6-amino-acid deletion plus several point mutations in the first Ig-like domain, in comparison to the CD22 b protein (20) . These mutations map to the C9 and C$ b-strands of one b-sheet, as can be deduced : NZB versus B6: P < 0.05; NZW versus B6: P < 0.01; DBA/2 versus B6: P < 0.01. Similar statistically significant differences were obtained when Cd22 a mice were compared with BALB/c and C3H mice. (B) Splenocytes were pre-treated with sialidase to remove sialic acids from the cellular surface and then stained. The proportion of probe-bound B cells after sialidase treatment was higher in Cd22 a than in Cd22 b mice, as shown by mean percentages (61 SD) in upper right quadrants. Significance by Student's t-test (n ¼ 3): NZB versus B6, BALB/c, C3H: not significant; NZW versus B6, BALB/c, C3H: P < 0.01; DBA/2 versus B6, BALB/c, C3H: P < 0.01. This was also corroborated by the mean fluorescence intensities of all B220 + cells: B6 CD22 ÿ/ÿ : 5, B6: 13, BALB/c: 10, C3H: 11, NZB: 18, NZW: 22, DBA/2: 17. One representative result of three independent experiments is shown. (27) and alignment of CD22 sequence with the sialoadhesin (28) . These C9 and C$ b-strands are far away from the sialic acid-binding pocket of the Siglecs, which is formed by b-strands A, F and G (27) . Therefore, the mutations present in these 'normal' forms of the CD22 a protein are unlikely to affect the sialic acidbinding site and to change the affinity of CD22 ligands.
In addition to the mutation mentioned above, Cd22 a also carries a short interspersed nucleotide element insertion in the second intron, leading to abnormal splicing of Cd22 a mRNA (21) . Thus, aberrant CD22 molecules are likely expressed on Cd22 a B cells with substantial deletions in the first Ig-like domain which constitutes the ligand-binding site (21) . Western blot analysis shows a slightly lower running CD22 protein in B cells from Cd22 a mice. This supports the possible expression of truncated isoforms of CD22, since the observed difference cannot be explained by a 6-aminoacid deletion present in the full-length CD22 a protein, as compared with the CD22 b protein (849 amino acids). Based on the sequence analysis on nine different aberrant CD22 mRNA species in Cd22 a mice (21), we expect that at least two isoforms (mCD22-VII and VIII) could express truncated forms of CD22, which have additional deletions of 34 and 62 amino acids. Notably, three others are likely to be unexpressed because of the presence of a premature stop codon. Since the relative abundance of these different CD22 mRNA transcripts has not been estimated, it is difficult to define the expression levels of aberrant CD22 proteins in relation to those of full-length CD22 protein. Clearly, further biochemical analysis is awaited to determine whether the majority of CD22 expressed in Cd22 a mice are indeed the truncated isoforms of CD22.
Possible expression of aberrant forms of CD22 likely impairs the binding of anti-CD22 CY34 mAb. The epitope for CY34 binding has been mapped to arginine at position 120 in the first Ig-like domain, in close vicinity to arginine at position 130, which is highly conserved within the Siglec family and required for sialic acid binding (28) . Therefore, the ligand-binding capacity of the aberrant forms of CD22 a is likely to be affected. In addition, it should also be stressed that one of the truncated isoforms (mCD22-VII) possibly expressed in Cd22 a B cells lacks arginines at position 130 and 137 (21) , which are involved in the ligand-binding activity (19) . Thus, a decreased ability of the aberrant CD22 a proteins to bind to endogenous cis ligands could explain the higher degree of unmasked CD22 on the surface of B cells from Cd22 a mice that we observed in experiments using synthetic 2,6Sia-containing probe. Significantly, we also observed that sialidase-treated Cd22 a B cells displayed a more pronounced increase in binding of this probe, as compared with Cd22 b B cells. This could be due to the fact that more of the CD22 b protein is bound in cis, thus rendering the sialic acids on Cd22 b B cells less accessible to sialidase treatment than on their Cd22 a counterparts. However, it should be stressed that CD22 a efficiently binds this artificial ligand, probably because of a higher avidity of the synthetic ligand than of the endogenous cis ligands, due to its oligomeric structure.
Additionally, expression of CD22 a might affect homodimerization of CD22. Indeed, an N-linked potential glycosylation site is missing in the first Ig-like domain of CD22 a , due to the 6-amino-acid deletion present in the Cd22 a gene (23). In the CD22 b molecule, this glycosylation site may carry carbohydrates, including 2,6Sia, which can be sterically well accessible to the sialic acid-binding domain, also present in the first Ig-like domain. Indirect evidence for such a model of homodimerization comes from experiments in which sialylation of CD22 protein prevented CD22-mediated adhesion (29) . Defective homodimerization could provide an alternative explanation why a higher fraction of CD22 is unbound in cis on Cd22 a B cells, but more experiments are needed to test this possibility.
Impaired ligand binding by CD22 in cis on the B-cell surface has previously been shown to affect BCR signaling. When CD22 ligand binding was prevented by a genetic or pharmacological approach, anti-IgM-stimulated B cells showed less tyrosine phosphorylation of CD22, less SHP-1 recruitment and a higher Ca 2+ mobilization (17, 18) . However, a recently established CD22 knock-in mouse with a mutation in the ligandbinding domain of CD22 did not confirm these findings (19) . In fact, we were unable to demonstrate significant differences in Ca 2+ influx after anti-IgM stimulation of B cells between the various Cd22 a and Cd22 b mouse strains. Nevertheless, it should be stressed that B cells expressing a mutant CD22 lacking the ligand-binding domain displayed a phenotype of activated B cells, which is characterized by reduced IgM expression and augmented MHC class II expression, similar to that of CD22 ÿ/ÿ B cells (3) (4) (5) (6) , and that CD22 ligand binding was involved in the regulation of BCR-mediated B-cell proliferation (19) . Our analysis of B6 Cd22 congenic mice revealed that Cd22 a B cells exhibit an activated phenotype (i.e. reduced surface IgM expression and increased surface MHC class II expression) similar to those of B cells expressing the mutant CD22. In view of the importance of CD22-CD22 ligand interaction in the regulation of B-cell activation, our data support the idea that the expression of the defective Cd22 a could contribute to enhanced B-cell activation, and thus favor the development of autoimmune responses in combination with other susceptibility alleles present in lupusprone mice.
The expression of aberrant CD22 molecules in Cd22 a mice may have significant consequences for B-cell responses to antigen, and in particular for the spontaneous production of autoantibodies. A recent study suggested that simultaneous interactions between B cells and target cells via BCR-autoantigen and CD22-CD22 ligand could be a mechanism to prevent activation of potentially autoreactive B cells (30) . Thus, in Cd22 a mice, lower basal expression levels and defective up-regulation of CD22 on potentially autoreactive B cells could favor the production of autoantibodies by reducing the BCR signaling threshold. In agreement, deficiency in CD22 expression, even at a heterozygous level, was able to promote the production of IgG anti-DNA autoantibodies in B6 mice (3, 21, 31) . Interval mapping analysis for lupus susceptibility loci revealed that an NZW locus that peaked in the vicinity of the Cd22 a gene was strongly linked with autoantibody production and lupus-like glomerulonephritis (32) (33) (34) . More recently, we have shown that B6 mice bearing an NZB chromosome 7 interval encompassing the Cd22 a gene spontaneously develop lupus-like autoimmune syndrome (24) . Clearly, further assessment of the functional capacities of the different allelic forms of CD22 and of the regulation of CD22 expression will help to better understand the role of CD22 polymorphism in the development of B-cell-mediated autoimmune diseases.
